Vivos Therapeutics, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -79.4% | -75.7% | -60.2% |
| FY2022 | -496.7% | -496.7% | -173.8% |
| FY2023 | -3,304.9% | -3,304.9% | -126.6% |
| FY2024 | -140.0% | -140.0% | -72.9% |
| FY2025 | 1,420.8% | 2,073.5% | -84.2% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | -79.4% | -75.7% | -60.2% |
| FY2022 | -496.7% | -496.7% | -173.8% |
| FY2023 | -3,304.9% | -3,304.9% | -126.6% |
| FY2024 | -140.0% | -140.0% | -72.9% |
| FY2025 | 1,420.8% | 2,073.5% | -84.2% |